カテゴリ： GlobalData, アメリカ, 企業調査

AmerisourceBergen Corp (ABC)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：AmerisourceBergen Corp (ABC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9872
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：80
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
AmerisourceBergen Corp (AmerisourceBergen) is a pharmaceutical sourcing and distribution services company that provides pharmaceutical products, business solutions and value-driving services that improve access to care. The company distributes a broad offering of brand-name, specialty brand-name, over-the-counter (OTC) healthcare products, generic pharmaceuticals, equipment, home healthcare supplies, outsourced compounded sterile preparations and related services. It serves numerous healthcare providers in the US and selected global markets, comprising independent and chain retail pharmacies, acute care hospitals and health systems, medical clinics, mail order pharmacies, medical and dialysis clinics, physician practices, long-term care and alternate site pharmacies, veterinarians and other customers. AmerisourceBergen is headquartered in Chesterbrook, Pennsylvania, the US.

AmerisourceBergen Corp (ABC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AmerisourceBergen Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AmerisourceBergen Corp, Medical Devices Deals, 2012 to YTD 2018 10
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
AmerisourceBergen And Profarma Distribuidora de Produtos Farma Forms Joint Venture 12
Equity Offering 13
AmerisourceBergen Raises USD1.17 Billion in Private Placement of Shares up on Exercise of Warrants 13
Debt Offering 14
AmerisourceBergen Raises USD500 Million in Public Offering of 4.3% Senior Notes Due 2047 14
AmerisourceBergen Raises USD750 Million in Public Offering of 3.45% Senior Notes Due 2027 16
AmerisourceBergen Raises USD500 Million in Public Offering of 3.4% Notes 18
AmerisourceBergen Raises USD600 Million in Public Offering of 1.15% Notes 20
Acquisition 22
Walgreens Boots Alliance May Acquire Remaining 74% Stake in AmerisourceBergen 22
AmerisourceBergen Completes Acquisition of 19.9% Stake in Profarma Distribuidora de Produtos Farma for USD61.7 Million 23
H. D. Smith Completes Acquisition Of Remaining 49% Interest In Triplefin 24
Kohl & Frisch Completes Acquisition Of AmerisourceBergen Canada For Up To US$100 Million 26
Walgreen And Alliance Boots Receive Regulatory Clearance To Acquire Up To 25% Stake In AmerisourceBergen 27
Triplefin Acquires Minority Stake In Specialty Pharmacy Nursing Network 29
H. D. Smith Wholesale Drug Completes Acquisition Of Valley Wholesale Drug 30
AmerisourceBergen Corp – Key Competitors 31
AmerisourceBergen Corp – Key Employees 32
AmerisourceBergen Corp – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 36
Strategy And Business Planning 36
Aug 29, 2018: ICS opens new third-party logistics pharmaceutical distribution center 36
Jun 19, 2017: AmerisourceBergen Structures Operating Model and Executive Leadership Team to Offer a More Cohesive and Unified Customer Experience, Enhance Growth and Drive Long-Term Value 37
Financial Announcements 38
Aug 02, 2018: AmerisourceBergen posts fiscal 2018 Q3 results 38
May 02, 2018: AmerisourceBergen Reports Fiscal 2018 Second Quarter Results 39
Feb 06, 2018: AmerisourceBergen Reports Fiscal 2018 First Quarter Results 42
Nov 02, 2017: AmerisourceBergen Reports Fiscal 2017 Fourth Quarter and Year End Results 45
Aug 03, 2017: AmerisourceBergen Reports Third Quarter Fiscal Year 2017 Results 50
May 04, 2017: AmerisourceBergen Reports Second Quarter Fiscal Year 2017 Results 53
Jan 31, 2017: AmerisourceBergen Reports First Quarter Fiscal Year 2017 Results 56
Corporate Communications 59
Sep 10, 2018: AmerisourceBergen Announces Financial Leadership Change 59
May 15, 2018: Lash Group Launches Artificial Intelligence-Powered Electronic Benefit Verification Solution May 2018 60
Oct 04, 2017: AmerisourceBergen, Blue Cross Blue Shield Association, Pfizer and Prime Therapeutics Join Walgreens to Combat Prescription Drug Abuse by Expanding Safe Medication Disposal Program 61
Sep 19, 2017: AmerisourceBergen and the AmerisourceBergen Foundation Commit More Than $100,000 to Support Victims of Hurricanes Harvey and Irma 63
Legal and Regulatory 64
Oct 01, 2018: AmerisourceBergen to Pay $625 million to settle civil fraud allegations resulting from its repackaging and sale of adulterated drugs and unapproved new drugs, double billing and providing kickbacks 64
Aug 15, 2017: City of Birmingham and Legal Counsel Baron & Budd, Greene Ketchum, Levin Papantonio File Suit Against Pharmaceutical Distributors for Role in Creating Opioid Crisis 67
Jul 10, 2017: AmerisourceBergen Recognized as “Best In Class” for Specialty Distribution Quality 68
Jun 23, 2017: CPPA Accredits US Bioservices, a part of AmerisourceBergen, for Specialty Pharmacy 69
Government and Public Interest 70
Mar 09, 2018: The Moyer Foundation Receives Grant from the AmerisourceBergen Foundation to Launch New Community Program for Children Living with Addiction in their Families 70
Feb 15, 2018: AmerisourceBergen Comments on DEA’s Creation of Transparency Resource to Help Distributors Combat Opioid Abuse 71
Nov 13, 2017: AmerisourceBergen Urges Policymakers to Support Regulator and Industry Data Transparency to More Effectively Combat Opioid Abuse 72
Product News 73
Feb 13, 2017: IntrinsiQ Specialty Solutions and ION Solutions Provide Independent Oncology, Urology Practices Improved Access to Clinical Trials with the Launch of AdvanceIQ Network 73
Other Significant Developments 74
May 30, 2018: US Bioservices Collaborates with MedImpact Direct to Support Hemophilia Patients 74
Dec 14, 2017: AmerisourceBergen Foundation Launches Municipal Support Program to Help Combat Opioid Abuse 75
Oct 04, 2017: Lash Group Launches Fusion, a New Technology Ecosystem to Power the Future of Patient Support Services 76
Aug 14, 2017: AmerisourceBergen Helps Innovators Navigate Commercialization for Cell and Gene Therapies 77
Jul 21, 2017: Good Neighbor Pharmacy Equips Independent Pharmacists to be Vital Source of Care in Today’s Healthcare Environment 78
Mar 28, 2017: AmerisourceBergen enhances specialty medication management, storage solution Cubixx 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80

List of Tables
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AmerisourceBergen Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AmerisourceBergen Corp, Deals By Therapy Area, 2012 to YTD 2018 9
AmerisourceBergen Corp, Medical Devices Deals, 2012 to YTD 2018 10
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AmerisourceBergen And Profarma Distribuidora de Produtos Farma Forms Joint Venture 12
AmerisourceBergen Raises USD1.17 Billion in Private Placement of Shares up on Exercise of Warrants 13
AmerisourceBergen Raises USD500 Million in Public Offering of 4.3% Senior Notes Due 2047 14
AmerisourceBergen Raises USD750 Million in Public Offering of 3.45% Senior Notes Due 2027 16
AmerisourceBergen Raises USD500 Million in Public Offering of 3.4% Notes 18
AmerisourceBergen Raises USD600 Million in Public Offering of 1.15% Notes 20
Walgreens Boots Alliance May Acquire Remaining 74% Stake in AmerisourceBergen 22
AmerisourceBergen Completes Acquisition of 19.9% Stake in Profarma Distribuidora de Produtos Farma for USD61.7 Million 23
H. D. Smith Completes Acquisition Of Remaining 49% Interest In Triplefin 24
Kohl & Frisch Completes Acquisition Of AmerisourceBergen Canada For Up To US$100 Million 26
Walgreen And Alliance Boots Receive Regulatory Clearance To Acquire Up To 25% Stake In AmerisourceBergen 27
Triplefin Acquires Minority Stake In Specialty Pharmacy Nursing Network 29
H. D. Smith Wholesale Drug Completes Acquisition Of Valley Wholesale Drug 30
AmerisourceBergen Corp, Key Competitors 31
AmerisourceBergen Corp, Key Employees 32
AmerisourceBergen Corp, Subsidiaries 34

List of Figures
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AmerisourceBergen Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AmerisourceBergen Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[AmerisourceBergen Corp (ABC)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • PIK-Group：企業のM&A・事業提携・投資動向
    PIK-Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's PIK-Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Interpace Diagnostics Group Inc (IDXG)-製薬・医療分野：企業M&A・提携分析
    Summary Interpace Diagnostics Group Inc (Interpace Diagnostics), formerly PDI Inc, is a developer of molecular diagnostics tests. The company offers PancraGen, a DNA based molecular test that aids in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its pathfinder platform; a …
  • The Reject Shop Ltd (TRS)：企業の財務・戦略的SWOT分析
    The Reject Shop Ltd (TRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Onxeo SA (ONXEO)：企業の財務・戦略的SWOT分析
    Summary Onxeo SA (Onxeo) is a manufacturer of drugs that offers development, and registration of orphan oncology drugs for the treatment of cancer. The company provides pipeline products such as livatag, belchop, beleodaq, amep, asidna and validive, among others. It offers drugs for the treatment of …
  • Petro Welt Technologies AG (O2C)：企業の財務・戦略的SWOT分析
    Petro Welt Technologies AG (O2C) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • GlaxoSmithKline Plc：企業の戦略・SWOT・財務情報
    GlaxoSmithKline Plc - Strategy, SWOT and Corporate Finance Report Summary GlaxoSmithKline Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • PT. SOHO Industri Pharmasi：製薬・医療：M&Aディール及び事業提携情報
    Summary PT. SOHO Industri Pharmasi (PT SOHO), a subsidiary of SOHO Global Health, is a pharmaceutical company that offers ethical, consumer health, herbal medicine and natural products. The company’s products include analgesic, anti-inflammatory, antipyretic, antibiotics, antifungal, antihistamine a …
  • Leica Microsystems GmbH-医療機器分野：企業M&A・提携分析
    Summary Leica Microsystems GmbH (Leica), a subsidiary of Danaher Corp is a medical device company that manufactures microstructures. The company manufactures, and markets microscopes and scientific instruments. Its products include light microscopes, confocal microscopes, stereo microscopes and macr …
  • Karachaganak Petroleum Operating BV：企業の戦略的SWOT分析
    Karachaganak Petroleum Operating BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • ConocoPhillips Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    ConocoPhillips Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary ConocoPhillips is an independent upstream oil and gas company. The company explore for, produce, transport and market crude oil, bitumen, natural gas, liquefied natural gas (LNG) and natural gas liqui …
  • Aveng Ltd (AEG)：企業の財務・戦略的SWOT分析
    Aveng Ltd (AEG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • New Image Group Ltd：企業の戦略的SWOT分析
    New Image Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Sarah Cannon Research Institute LLC-製薬・医療分野：企業M&A・提携分析
    Summary Sarah Cannon Research Institute LLC (SCRI) is a research institute that offers integrated cancer services. The institute conducts clinical research programs for advancing cancer therapies. Its services include blood cancer network, cancer care overview, cardiovascular research, contract rese …
  • Vienna Insurance Group AG：企業のM&A・事業提携・投資動向
    Vienna Insurance Group AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vienna Insurance Group AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Huttig Building Products Inc：企業の戦略・SWOT・財務分析
    Huttig Building Products Inc - Strategy, SWOT and Corporate Finance Report Summary Huttig Building Products Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Pearson plc：企業の戦略・SWOT・財務情報
    Pearson plc - Strategy, SWOT and Corporate Finance Report Summary Pearson plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Concordia International Corp (CXR)-製薬・医療分野：企業M&A・提携分析
    Summary Concordia International Corp (Concordia), formerly Concordia Healthcare Corp is a healthcare products provider that offers orphan drugs. The company undertakes the management and acquisition of legacy pharmaceutical products, orphan drugs and medical devices for diabetics. Its products compr …
  • KLA-Tencor Corporation (KLAC)：企業の財務・戦略的SWOT分析
    KLA-Tencor Corporation (KLAC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Corcept Therapeutics Inc (CORT)：企業の財務・戦略的SWOT分析
    Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • EOG Resources Inc (EOG)：石油・ガス：M&Aディール及び事業提携情報
    Summary EOG Resources Inc (EOG) is an independent upstream oil and gas company. The company, along with its subsidiaries, explores for, develops and produces crude oil and natural gas. EOG has operations in the US, Canada, Trinidad, the UK and China. Its holds licenses for assets in in Eagle Ford, B …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆